Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
1.15
USD
|
+1.32%
|
|
+5.50%
|
+32.95%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,204
|
1,139
|
485.8
|
384.9
|
99.07
|
135.4
|
-
|
-
|
Enterprise Value (EV)
1 |
1,204
|
983.8
|
426.4
|
277.1
|
99.07
|
135.4
|
135.4
|
135.4
|
P/E ratio
|
-5.95
x
|
-5.69
x
|
-3.9
x
|
-1.68
x
|
-0.69
x
|
-0.93
x
|
-1.39
x
|
-1.92
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
29.4
x
|
10.5
x
|
2.32
x
|
2.45
x
|
0.68
x
|
0.94
x
|
0.81
x
|
0.58
x
|
EV / Revenue
|
29.4
x
|
10.5
x
|
2.32
x
|
2.45
x
|
0.68
x
|
0.94
x
|
0.81
x
|
0.58
x
|
EV / EBITDA
|
-6,392,346
x
|
-6,667,563
x
|
-4,983,180
x
|
-2,718,759
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-6,301,093
x
|
-7,104,046
x
|
-4,526,036
x
|
-2,571,788
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
25.2
x
|
22.1
x
|
-6.07
x
|
-16.7
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
62,790
|
73,601
|
75,547
|
113,213
|
114,534
|
117,710
|
-
|
-
|
Reference price
2 |
19.17
|
15.48
|
6.430
|
3.400
|
0.8650
|
1.150
|
1.150
|
1.150
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/8/22
|
2/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
40.89
|
108.1
|
209.8
|
157.1
|
146
|
144.7
|
166.5
|
233.6
|
EBITDA
|
-188.3
|
-170.9
|
-97.48
|
-141.6
|
-
|
-
|
-
|
-
|
EBIT
1 |
-189.3
|
-171.8
|
-98.27
|
-142.2
|
-129.5
|
-123.5
|
-112.2
|
-73.35
|
Operating Margin
|
-462.85%
|
-159%
|
-46.84%
|
-90.53%
|
-88.71%
|
-85.36%
|
-67.38%
|
-31.41%
|
Earnings before Tax (EBT)
1 |
-199.6
|
-196
|
-123.8
|
-164.9
|
-142.8
|
-145
|
-135.6
|
-108.9
|
Net income
1 |
-199.6
|
-196.3
|
-124.1
|
-165.3
|
-143.1
|
-146
|
-138.1
|
-108.9
|
Net margin
|
-488.08%
|
-181.59%
|
-59.14%
|
-105.23%
|
-97.99%
|
-100.96%
|
-82.97%
|
-46.62%
|
EPS
2 |
-3.220
|
-2.720
|
-1.650
|
-2.020
|
-1.250
|
-1.232
|
-0.8250
|
-0.6000
|
Free Cash Flow
|
-191
|
-160.4
|
-107.3
|
-149.7
|
-
|
-
|
-
|
-
|
FCF margin
|
-467.14%
|
-148.38%
|
-51.15%
|
-95.29%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/8/22
|
2/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
126.3
|
47.67
|
39.68
|
36.14
|
33.58
|
38.7
|
37.58
|
36.01
|
33.75
|
33.13
|
36.21
|
37.7
|
37.61
|
44.49
|
48.51
|
EBITDA
|
47.1
|
-34.41
|
-36.6
|
-30.66
|
-33.76
|
-30.61
|
-29.49
|
-31.18
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
46.96
|
-34.59
|
-42.91
|
-30.84
|
-33.87
|
-30.9
|
-29.57
|
-31.26
|
-37.81
|
-33.76
|
-30.41
|
-29.22
|
-30.09
|
-22.52
|
-24.18
|
Operating Margin
|
37.19%
|
-72.55%
|
-108.14%
|
-85.32%
|
-100.86%
|
-79.85%
|
-78.7%
|
-86.81%
|
-112.03%
|
-101.91%
|
-83.97%
|
-77.5%
|
-80.02%
|
-50.63%
|
-49.84%
|
Earnings before Tax (EBT)
1 |
38.6
|
-41.27
|
-48.94
|
-36.28
|
-38.43
|
-34.07
|
-32.5
|
-34.49
|
-41.71
|
-37.29
|
-36.18
|
-34.72
|
-36.86
|
-
|
-
|
Net income
1 |
38.72
|
-41.4
|
-49.06
|
-36.32
|
-38.51
|
-34.13
|
-32.63
|
-34.51
|
-41.84
|
-37.36
|
-37.06
|
-35.14
|
-36.5
|
-
|
-
|
Net margin
|
30.66%
|
-86.84%
|
-123.65%
|
-100.5%
|
-114.67%
|
-88.19%
|
-86.83%
|
-95.83%
|
-123.97%
|
-112.79%
|
-102.33%
|
-93.19%
|
-97.05%
|
-
|
-
|
EPS
2 |
0.4600
|
-0.5300
|
-0.6200
|
-0.4500
|
-0.4300
|
-0.3000
|
-0.2900
|
-0.3000
|
-0.3600
|
-0.3200
|
-0.3150
|
-0.2975
|
-0.3025
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/8/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/15/23
|
5/4/23
|
8/2/23
|
11/2/23
|
2/29/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
156
|
59.3
|
108
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-191
|
-160
|
-107
|
-150
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-171%
|
-391%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-62.7%
|
-64.6%
|
-40.1%
|
-49.8%
|
-
|
-
|
-
|
-
|
Assets
1 |
318.1
|
304
|
309.2
|
331.7
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
0.7600
|
0.7000
|
-1.060
|
-0.2000
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.21
|
0.15
|
0.21
|
0.12
|
-
|
-
|
-
|
-
|
Capex / Sales
|
0.5%
|
0.13%
|
0.1%
|
0.08%
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/8/22
|
2/15/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
1.15
USD Average target price
5.214
USD Spread / Average Target +353.42% Consensus |
1st Jan change
|
Capi.
|
---|
| +32.95% | 135M | | +9.42% | 115B | | +11.84% | 106B | | -1.05% | 21.96B | | -14.15% | 21.84B | | -5.29% | 19.21B | | -4.16% | 18.08B | | -38.29% | 17.71B | | +7.99% | 14.32B | | +36.24% | 12.42B |
Bio Therapeutic Drugs
|